

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A pharmaceutical composition comprising, in admixture, a first active ingredient which is selected from the group consisting of 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] and a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof ~~a PDE4 inhibitor, a PDE3/4 inhibitor and their pharmaceutically acceptable derivatives~~, and a second active ingredient which is selected from the group consisting of (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: CETIRIZINE] and a pharmaceutically acceptable salt thereof,
wherein the first active ingredient and the second active ingredient are the only active ingredients present in the composition ~~a histamine receptor-antagonist and its pharmaceutically acceptable derivatives~~.
2. (Currently amended) ~~[[A]]~~ The pharmaceutical composition according to claim 1, wherein the first ~~and/or second~~ active ingredient is 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] ~~in the form of a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a~~

~~salt, solvate of a salt, N-oxide, salt of an N-oxide, hydrate of an N-oxide or solvate of an N-oxide.~~

3. – 16. (Cancelled)

17. (Currently amended) A pharmaceutical product comprising, in combination, a preparation of a first active ingredient which is selected from the group consisting of 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] and a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof ~~a PDE4 inhibitor, a PDE3/4 inhibitor and their pharmaceutically acceptable derivatives~~, and a preparation of a second active ingredient which is selected from the group consisting of (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: CETIRIZINE] and a pharmaceutically acceptable salt thereof ~~a histamine receptor antagonist and its pharmaceutically acceptable derivatives~~, for simultaneous, sequential or separate use in therapy,
- wherein the first active ingredient and the second active ingredient are the only active ingredients present in the pharmaceutical product.

18. (Currently amended) ~~[[A]]~~ The pharmaceutical product according to claim 17, wherein the first ~~and/or second~~ active ingredient is 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] in

the form of a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a salt, solvate of a salt, N-oxide, salt of an N-oxide, hydrate of an N-oxide or solvate of an N-oxide.

19. – 27. (Cancelled)

28. (Currently amended) A kit comprising a preparation of a first active ingredient which is selected from the group consisting of 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] and a pharmaceutically acceptable salt, N-oxide or salt of an N-oxide thereof a PDE4 inhibitor, a PDE3/4 inhibitor and their pharmaceutically acceptable derivatives, a preparation of a second active ingredient which is selected from the group consisting of (plus/minus)-[2-[4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl]ethoxy]-acetic acid [INN: CETIRIZINE] and a pharmaceutically acceptable salt thereof a histamine receptor antagonist and its pharmaceutically acceptable derivatives, and instructions for simultaneous, sequential or separate administration to the patient in need thereof,
- wherein the first active ingredient and the second active ingredient are the only active ingredients present in the pharmaceutical product.

29. (Currently amended) **[[A]]** The kit according to claim 28, wherein the first and/or second active ingredient is 3-Cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-

~~dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] in the form of a
pharmaceutically acceptable salt, hydrate, solvate, hydrate of a salt, solvate of a
salt, N-oxide, salt of an N-oxide, hydrate of an N-oxide or solvate of an N-oxide.~~

30. – 47. (Cancelled)